Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021

Wesley H. Self; Mark W. Tenforde; Jillian P. Rhoads; Manjusha Gaglani; Adit A. Ginde; David J. Douin; Samantha M. Olson; H. Keipp Talbot; Jonathan D. Casey; Nicholas M. Mohr; Anne Zepeski; Tresa McNeal; Shekhar Ghamande; Kevin W. Gibbs; D. Clark Files; David N. Hager; Arber Shehu; Matthew E. Prekker; Heidi L. Erickson; Michelle N. Gong; Amira Mohamed; Daniel J. Henning; Jay S. Steingrub; Ithan D. Peltan; Samuel M. Brown; Emily T. Martin; Arnold S. Monto; Akram Khan; Catherine L. Hough; Laurence W. Busse; Caitlin C.Ten Lohuis; Abhijit Duggal; Jennifer G. Wilson; Alexandra June Gordon; Nida Qadir; Steven Y. Chang; Christopher Mallow; Carolina Rivas; Hilary M. Babcock; Jennie H. Kwon; Matthew C. Exline; Natasha Halasa; James D. Chappell; Adam S. Lauring; Carlos G. Grijalva; Todd W. Rice; Ian D. Jones; William B. Stubblefield; Adrienne Baughman; Kelsey N. Womack; Christopher J. Lindsell; Kimberly W. Hart; Yuwei Zhu; Lisa Mills; Sandra N. Lester; Megan M. Stump; Eric A. Naioti; Miwako Kobayashi; Jennifer R. Verani; Natalie J. Thornburg; Manish M. Patel

doi:10.15585/MMWR.MM7038E1

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021

Wesley H. Self, Mark W. Tenforde, Jillian P. Rhoads, Manjusha Gaglani, Adit A. Ginde, David J. Douin, Samantha M. Olson, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Tresa McNeal, Shekhar Ghamande, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Heidi L. Erickson, Michelle N. GongAmira Mohamed, Daniel J. Henning, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Arnold S. Monto, Akram Khan, Catherine L. Hough, Laurence W. Busse, Caitlin C.Ten Lohuis, Abhijit Duggal, Jennifer G. Wilson, Alexandra June Gordon, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Hilary M. Babcock, Jennie H. Kwon, Matthew C. Exline, Natasha Halasa, James D. Chappell, Adam S. Lauring, Carlos G. Grijalva, Todd W. Rice, Ian D. Jones, William B. Stubblefield, Adrienne Baughman, Kelsey N. Womack, Christopher J. Lindsell, Kimberly W. Hart, Yuwei Zhu, Lisa Mills, Sandra N. Lester, Megan M. Stump, Eric A. Naioti, Miwako Kobayashi, Jennifer R. Verani, Natalie J. Thornburg, Manish M. Patel

Medicine

Research output: Contribution to journal › Article › peer-review

292 Scopus citations

Abstract

What is already known about this topic? Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States. What is added by this report? Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%). What are the implications for public health practice? Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.

Original language	English (US)
Pages (from-to)	1337-1343
Number of pages	7
Journal	Morbidity and Mortality Weekly Report
Volume	70
Issue number	38
DOIs	https://doi.org/10.15585/MMWR.MM7038E1
State	Published - Sep 2021

ASJC Scopus subject areas

Health(social science)
Health Information Management
Health, Toxicology and Mutagenesis
Epidemiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.15585/MMWR.MM7038E1

Fingerprint

Dive into the research topics of 'Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021'. Together they form a unique fingerprint.

Cite this

Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., ... Patel, M. M. (2021). Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021. Morbidity and Mortality Weekly Report, 70(38), 1337-1343. https://doi.org/10.15585/MMWR.MM7038E1

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021. / Self, Wesley H.; Tenforde, Mark W.; Rhoads, Jillian P. et al.
In: Morbidity and Mortality Weekly Report, Vol. 70, No. 38, 09.2021, p. 1337-1343.

Research output: Contribution to journal › Article › peer-review

Self, WH, Tenforde, MW, Rhoads, JP, Gaglani, M, Ginde, AA, Douin, DJ, Olson, SM, Talbot, HK, Casey, JD, Mohr, NM, Zepeski, A, McNeal, T, Ghamande, S, Gibbs, KW, Files, DC, Hager, DN, Shehu, A, Prekker, ME, Erickson, HL, Gong, MN , Mohamed, A, Henning, DJ, Steingrub, JS, Peltan, ID, Brown, SM, Martin, ET, Monto, AS, Khan, A, Hough, CL, Busse, LW, Lohuis, CCT, Duggal, A, Wilson, JG, Gordon, AJ, Qadir, N, Chang, SY, Mallow, C, Rivas, C, Babcock, HM, Kwon, JH, Exline, MC, Halasa, N, Chappell, JD, Lauring, AS, Grijalva, CG, Rice, TW, Jones, ID, Stubblefield, WB, Baughman, A, Womack, KN, Lindsell, CJ, Hart, KW, Zhu, Y, Mills, L, Lester, SN, Stump, MM, Naioti, EA, Kobayashi, M, Verani, JR, Thornburg, NJ & Patel, MM 2021, 'Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021', Morbidity and Mortality Weekly Report, vol. 70, no. 38, pp. 1337-1343. https://doi.org/10.15585/MMWR.MM7038E1

Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021. Morbidity and Mortality Weekly Report. 2021 Sep;70(38):1337-1343. doi: 10.15585/MMWR.MM7038E1

Self, Wesley H. ; Tenforde, Mark W. ; Rhoads, Jillian P. et al. / Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021. In: Morbidity and Mortality Weekly Report. 2021 ; Vol. 70, No. 38. pp. 1337-1343.

@article{df9cd06b9d2a4b7b9cd6050ce2fec981,

title = "Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021",

abstract = "What is already known about this topic? Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States. What is added by this report? Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%). What are the implications for public health practice? Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.",

author = "Self, {Wesley H.} and Tenforde, {Mark W.} and Rhoads, {Jillian P.} and Manjusha Gaglani and Ginde, {Adit A.} and Douin, {David J.} and Olson, {Samantha M.} and Talbot, {H. Keipp} and Casey, {Jonathan D.} and Mohr, {Nicholas M.} and Anne Zepeski and Tresa McNeal and Shekhar Ghamande and Gibbs, {Kevin W.} and Files, {D. Clark} and Hager, {David N.} and Arber Shehu and Prekker, {Matthew E.} and Erickson, {Heidi L.} and Gong, {Michelle N.} and Amira Mohamed and Henning, {Daniel J.} and Steingrub, {Jay S.} and Peltan, {Ithan D.} and Brown, {Samuel M.} and Martin, {Emily T.} and Monto, {Arnold S.} and Akram Khan and Hough, {Catherine L.} and Busse, {Laurence W.} and Lohuis, {Caitlin C.Ten} and Abhijit Duggal and Wilson, {Jennifer G.} and Gordon, {Alexandra June} and Nida Qadir and Chang, {Steven Y.} and Christopher Mallow and Carolina Rivas and Babcock, {Hilary M.} and Kwon, {Jennie H.} and Exline, {Matthew C.} and Natasha Halasa and Chappell, {James D.} and Lauring, {Adam S.} and Grijalva, {Carlos G.} and Rice, {Todd W.} and Jones, {Ian D.} and Stubblefield, {William B.} and Adrienne Baughman and Womack, {Kelsey N.} and Lindsell, {Christopher J.} and Hart, {Kimberly W.} and Yuwei Zhu and Lisa Mills and Lester, {Sandra N.} and Stump, {Megan M.} and Naioti, {Eric A.} and Miwako Kobayashi and Verani, {Jennifer R.} and Thornburg, {Natalie J.} and Patel, {Manish M.}",

year = "2021",

month = sep,

doi = "10.15585/MMWR.MM7038E1",

language = "English (US)",

volume = "70",

pages = "1337--1343",

journal = "Morbidity and Mortality Weekly Report",

issn = "0149-2195",

publisher = "Department of Health and Human Services",

number = "38",

}

TY - JOUR

T1 - Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021

AU - Self, Wesley H.

AU - Tenforde, Mark W.

AU - Rhoads, Jillian P.

AU - Gaglani, Manjusha

AU - Ginde, Adit A.

AU - Douin, David J.

AU - Olson, Samantha M.

AU - Talbot, H. Keipp

AU - Casey, Jonathan D.

AU - Mohr, Nicholas M.

AU - Zepeski, Anne

AU - McNeal, Tresa

AU - Ghamande, Shekhar

AU - Gibbs, Kevin W.

AU - Files, D. Clark

AU - Hager, David N.

AU - Shehu, Arber

AU - Prekker, Matthew E.

AU - Erickson, Heidi L.

AU - Gong, Michelle N.

AU - Mohamed, Amira

AU - Henning, Daniel J.

AU - Steingrub, Jay S.

AU - Peltan, Ithan D.

AU - Brown, Samuel M.

AU - Martin, Emily T.

AU - Monto, Arnold S.

AU - Khan, Akram

AU - Hough, Catherine L.

AU - Busse, Laurence W.

AU - Lohuis, Caitlin C.Ten

AU - Duggal, Abhijit

AU - Wilson, Jennifer G.

AU - Gordon, Alexandra June

AU - Qadir, Nida

AU - Chang, Steven Y.

AU - Mallow, Christopher

AU - Rivas, Carolina

AU - Babcock, Hilary M.

AU - Kwon, Jennie H.

AU - Exline, Matthew C.

AU - Halasa, Natasha

AU - Chappell, James D.

AU - Lauring, Adam S.

AU - Grijalva, Carlos G.

AU - Rice, Todd W.

AU - Jones, Ian D.

AU - Stubblefield, William B.

AU - Baughman, Adrienne

AU - Womack, Kelsey N.

AU - Lindsell, Christopher J.

AU - Hart, Kimberly W.

AU - Zhu, Yuwei

AU - Mills, Lisa

AU - Lester, Sandra N.

AU - Stump, Megan M.

AU - Naioti, Eric A.

AU - Kobayashi, Miwako

AU - Verani, Jennifer R.

AU - Thornburg, Natalie J.

AU - Patel, Manish M.

PY - 2021/9

Y1 - 2021/9

N2 - What is already known about this topic? Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States. What is added by this report? Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%). What are the implications for public health practice? Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.

AB - What is already known about this topic? Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United States. What is added by this report? Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%). What are the implications for public health practice? Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.

UR - http://www.scopus.com/inward/record.url?scp=85116863680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116863680&partnerID=8YFLogxK

U2 - 10.15585/MMWR.MM7038E1

DO - 10.15585/MMWR.MM7038E1

M3 - Article

C2 - 34555004

AN - SCOPUS:85116863680

SN - 0149-2195

VL - 70

SP - 1337

EP - 1343

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

IS - 38

ER -

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations among Adults without Immunocompromising Conditions - United States, March-August 2021

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this